Evidence map›Paper›PMID 30948791›Full record

ArticleScientific reports2019

Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues.

Yi Chen, Qi Shen, Sharla L White, Yesim Gokmen-Polar, Sunil Badve, Laurie J Goodman

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Multidimensional Imaging of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2023
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yi ChenClearLight Biotechnologies, LLC (formerly known as ClearLight Diagnostics, LLC), 428 Oakmead Pkwy, Sunnyvale, CA, 94085, USA.
Qi ShenClearLight Biotechnologies, LLC (formerly known as ClearLight Diagnostics, LLC), 428 Oakmead Pkwy, Sunnyvale, CA, 94085, USA.
Sharla L WhiteClearLight Biotechnologies, LLC (formerly known as ClearLight Diagnostics, LLC), 428 Oakmead Pkwy, Sunnyvale, CA, 94085, USA.
Yesim Gokmen-PolarDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Sunil BadveDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.ORCID http://orcid.org/0000-0001-8861-9980
Laurie J GoodmanClearLight Biotechnologies, LLC (formerly known as ClearLight Diagnostics, LLC), 428 Oakmead Pkwy, Sunnyvale, CA, 94085, USA. lgoodman@clearlightbiotech.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment can be spatially heterogenous, which makes it challenging to fully characterize with standard 2D histology-based methods. In this study, we determined the feasibility of a CLARITY tissue-processing approach to analyze biopsies from breast cancer patients. Formalin-fixed human breast cancer core-needle biopsy specimens, were embedded, lipid-cleared, and multiplexed immunostained to identify key biomarkers (pan-cytokeratin, Ki67, CD3). Confocal microscopy was then used to image the specimens after refractive index matching. These data sets were then quantitatively compared to conventional slide-based FFPE histology. Using CLARITY, the gross and cellular morphology of the tissues were well preserved, and high optical transparency was achieved, with the exception of fibrotic regions. Specific staining of various cellular and nuclear markers was achieved using optimized antibody conditions. Manually determined composite Ki67 scores from the CLARITY datasets agreed with histology results. However, the CLARITY datasets (3D) revealed variation in the intra-tumoral Ki67 expression that was not evident in individual FFPE sections (2D). We further demonstrated that archived FFPE clinical specimens can be CLARITY-processed, immunostained, and imaged. In short, CLARITY-processed specimens may enable a more accurate, unbiased analysis of tumor samples in comparison to conventional slide-based histology, thus allowing for improved visualization of intra-tumoral heterogeneity.

Indexed as

AnimalsBiomarkers, TumorBiopsyBiopsy, Large-Core NeedleBreastBreast NeoplasmsColoring AgentsFemaleFormaldehydeHumansImaging, Three-DimensionalMCF-7 CellsMiceMicroscopy, ConfocalParaffin EmbeddingStaining and LabelingBiomarkers, TumorColoring AgentsFormaldehyde

Identifiers

PMID30948791
PMCPMC6449377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.